Abstract
Radioimmunotherapy (RIT) is effective in treating relapsed/refractory follicular lymphoma (FL), with durable remissions in first-line consolidation. We hypothesized that RIT with ibritumomab tiuxetan (Zevalin®) would result in durable remissions by eliminating minimal residual disease after cytoreduction. Patients with FL received 2 cycles of ESHAP (etoposide, methylprednisolone, cytarabine, cisplatin) every 28 days, followed by Zevalin 4-6 weeks later if there was no disease progression and bone marrow biopsy showed < 25% involvement. Twenty-eight patients were treated, with a median age of 61 years, median of 3 prior therapies, 49% high-risk disease (Follicular Lymphoma International Prognostic Index, FLIPI), and 39% progressive disease. Three patients did not receive Zevalin due to residual bone marrow involvement. The main toxicities were cytopenias, with 11% febrile neutropenia. The overall response rate (ORR) was 72%, with 45% achieving complete response. With a median follow-up of 73 months, 1-year progression-free survival (PFS) was 38%, and median PFS was 10 months, but median overall survival (OS) was not reached. The study did not reach its primary endpoint of a 1-year PFS of 67.3%. Reasons for this could include low...Continue Reading
References
Jun 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W S VelasquezF Cabanillas
Oct 23, 1997·Hematology/oncology Clinics of North America·E J Rodriguez-Monge, F Cabanillas
May 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas E WitzigChristine A White
Mar 16, 2004·Blood·Leo I GordonChristine A White
Aug 27, 2005·Blood·Wolfgang HiddemannMichael Unterhalt
May 13, 2006·Leukemia & Lymphoma·Christos EmmanouilidesArturo Molina
Mar 24, 2007·Cancer·Thomas E WitzigGregory A Wiseman
Aug 22, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Myron S CzuczmanArturo Molina
Mar 5, 2008·Cancer Chemotherapy and Pharmacology·Vincent Launay-VacherUNKNOWN European Society of Clinical Pharmacy Special Interest Group on Cancer Care
May 27, 2008·Blood·Ajay K GopalJohn M Pagel
Jul 30, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert MarcusGeorge Stein
Oct 16, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Franck MorschhauserAnton Hagenbeek
Dec 13, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Oliver W PressRichard I Fisher
Apr 3, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Franck MorschhauserAnton Hagenbeek
Feb 14, 2015·Leukemia & Lymphoma·Jonathan ReissPeter Martin
Jun 30, 2015·Experimental Hematology & Oncology·Francesco PisaniMirella Marino
Jul 1, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carla CasuloJonathan W Friedberg
Feb 6, 2016·British Journal of Haematology·Tim M IllidgePeter W M Johnson
Mar 19, 2016·Blood·Brad S Kahl, David T Yang
Citations
Apr 2, 2019·International Reviews of Immunology·Mahsa EskianNima Rezaei
Dec 6, 2018·British Journal of Haematology·Karin HohlochChristian W Scholz
Dec 23, 2020·Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine·G F SteynM R van Heerden
Apr 2, 2021·ChemMedChem·Natalia Herrero ÁlvarezJason S Lewis
Aug 25, 2021·Acta Oncologica·Johan BlakkisrudCaroline Stokke